Molecular Pharmacology Program
The Daniel Heller Lab
Cancer Nanomedicine Laboratory
We are a biomedical engineering laboratory that develops nanotechnologies to advance breakthroughs in the research, diagnosis, and treatment of cancer and allied diseases. We develop drug delivery technologies to target therapies to disease sites, advanced diagnostics to detect disease at earlier stages, and nanosensors to accelerate the discovery of new therapies. Please check out our recent innovations using the “View Lab Overview” button below…
M Kim, C Chen, P Wang, JJ Mulvey, Y Yang, C Wun, M Antman-Passig, H-B Luo, S Cho, K Long-Roche, LV Ramanathan, A Jagota, M Zheng, Y Wang, DA Heller*. “Machine-Learning-Based Detection of an Ovarian Cancer Disease Fingerprint from Serum via Quantum Defect-Modified Carbon Nanotube Arrays.” Nature Biomedical Engineering (2022). https://www.mskcc.org/news/sensor-sniffs-cancer-using-artificial-intelligence
D Tylawsky, H Kiguchi, J Vaynshteyn, J Gerwin, J Shah, T Islam, M Snuderl, M Greenblatt, D Boué, Y Shamay, P Raju*, DA Heller* “P-selectin Targeting Stimulates Caveolin-1-Mediated Endothelial Transcytosis in Medulloblastoma.” (2021) Preprint. https://doi.org/10.21203/rs.3.rs-658944/v1
Z Yaari, Y Yang, E Apfelbaum, C Cupo, A Settle, Q Cullen, W Cai, K Long Roche, DA Levine, M Fleisher, L Ramanathan, M Zheng, A Jagota, DA Heller*. ”A Perception-Based Machine-Perception Nanosensor Platform to Detect Cancer Biomarkers.” Science Advances 7 (2021) eabj0852. MSK News: https://www.mskcc.org/news/detect-ovarian-cancer-early-researchers-look-nanotechnology
TV Galassi, PV Jena, J Shah, G Ao, E Molitor, Y Bram, A Frankel, J Park, J Jessurun, DS Ory, A Haimovitz-Friedman, D Roxbury, J Mittal, M Zheng, R E Schwartz, DA Heller*. “An Optical Nanoreporter of Endolysosomal Lipid Accumulation Reveals Enduring Effects of Diet on Hepatic Macrophages In Vivo.” Science Translational Medicine 10 (2018) eaar2680.
Y Shamay, J Shah, DF Tschaharganeh, D Roxbury, J Budhathoki-Uprety, M Işık, A Mizrachi, K Nawaly, JL Sugarman, E Baut, MR Neiman, DC Johnson, R Sridharan, KL Chu, VK Rajasekhar, JD Chodera, SW Lowe, DA Heller*, “Quantitative Self-Assembly Prediction Yields Targeted Nanomedicines” Nature Materials (2018)
Daniel A. Heller, PhD
- Biomedical engineer Daniel Heller is Head of the Cancer Nanotechnology Laboratory, which invents disruptive technologies to revolutionize the diagnosis and treatment of cancer and allied diseases.
- PhD, University of Illinois at Urbana-Champaign
- BS in Biochemistry from University of Delaware (2014)
- BS in Biology (Cell Molecular and Genetics) from University of Delaware (2014)
- American Institute for Medical and Biological Engineering (AIMBE) Fellow (2021)
- Pharmacology Teaching and Mentoring Award, Weill Cornell Graduate School (2020)
- American Cancer Society Research Scholar (2018)
- NSF CAREER Award (2018)
- Pershing Square Sohn Prize for Young Innovators in Cancer Research (2017)
- NIH Director’s New Innovator Award (2012)
- Damon Runyon Cancer Research Foundation Postdoctoral Fellowship (2010)
- Beckman Institute Graduate Fellowship (2006)
Lab News & Events
Congratulations to Naxhije Berisha - Tow Fellowship Awardee!
Congratulations to Dr. Mijin Kim - Kravis WiSE Postdoctoral Fellowship Winner!
Congratulations to Stephen Ruiz - awarded the MERIT Mandel Graduate Fellowship!
Congratulations to Magdalini Panagiotakopoulos – Tow Postdoctoral Fellowship Awardee!
Congratulations to Dr. Mijin Kim – MIT Technology Review 35 Under 35 Innovator!
Congratulations to Magdalini Panagiotakopoulos on winning the Controlled Release Society Poster Prize
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Daniel A. Heller discloses the following relationships and financial interests:
Mediphage Bioceuticals, Inc.
Ownership / Equity Interests; Provision of Services (uncompensated)
Ownership / Equity Interests
Nirova BioSense, Inc.
Ownership / Equity Interests
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.